As of December 31, 2024, the WBDR includes data from over 17,000 individuals across 124 hemophilia treatment centres (HTCs) in 47 countries. This growing body of data offers insights into care patterns, disparities, and treatment challenges experienced by PWH and PwVWD.
The 2024 WBDR Impact Report details a year of significant progress in data collection, program development, and global collaboration. It highlights how WBDR data is being used to identify gaps in care, inform research, and strengthen national and international advocacy efforts aimed at improving health outcomes and promoting equity.
Here are some key facts pulled from the report:
The WBDR continues to serve as a global benchmark for understanding clinical practices and addressing inequalities in care, and its success is due to the commitment of the healthcare providers, individuals with bleeding disorders, and treatment centres who contributed their time and data to this important endeavour.
The WFH encourages additional HTCs to join the WBDR initiative so that we can continue to expand this important offering for our community. By doing so, they will help support our shared mission of Treatment for All.
To read the WBDR Impact Report, please click here. To find out more about the WBDR, pleased click here.
The WBDR is made possible by the support of our visionary partner Sobi, and our collaborating partners Grifols, F. Hoffman-La Roche, Novo Nordisk, Pfizer and Sanofi.